Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Tumor Vaccines and PD-L1 Blockade in Surgically Resected Pancreatic Cancer
NCT04161755Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2019
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autogene cevumeran in pancreatic cancer (PC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Drug related toxicity at 2 years. Started Dec 2019; status: active, not recruiting.
02
Drugs
autogene cevumeran
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04161755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161755.